A prospective analysis of imatinib-induced c-KIT modulation in ovarian cancer: A phase II clinical study with proteomic profiling

Cancer

Volumn 110, Issue 2, 2007, Pages 309-317

  Posadas, Edwin M ^a   Kwitkowski, Virginia ^a   Kotz, Herbert L ^a   Espina, Virginia ^a   Minasian, Lori ^a   Tchabo, Nana ^a   Premkumar, Ahalya ^a   Hussain, Mahrukh M ^a   Chang, Richard ^b   Steinberg, Seth M ^a   Kohn, Elise C ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

C kit; Clinical trial; Ovarian cancer; Protein arrays; Proteomics

Indexed keywords

CYTOKINE; EPIDERMAL GROWTH FACTOR RECEPTOR; IMATINIB; INTERLEUKIN 6; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN HYDROLYSATE; STEM CELL FACTOR;

ADULT; ANEMIA; ARTICLE; ASCITES; BLOOD SAMPLING; CLINICAL TRIAL; CONTINUOUS INFUSION; CYTOPENIA; DRUG EFFECT; DYSPEPSIA; EDEMA; FACE EDEMA; FATIGUE; FEMALE; FLUID RETENTION; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; HUMAN; HUMAN TISSUE; HYPOALBUMINEMIA; HYPOTENSION; MICRODISSECTION; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVARY CANCER; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN MICROARRAY; PROTEIN PHOSPHORYLATION; PROTEOMICS; SIDE EFFECT; TUMOR BIOPSY;

ADULT; ANTINEOPLASTIC AGENTS; ASCITES; CYTOKINES; FEMALE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PIPERAZINES; PROSPECTIVE STUDIES; PROTEOME; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; TREATMENT OUTCOME;

EID: 34547160422     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22757     Document Type: Article

References (49)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006;56:106-130.
2. Ozols RF. Systemic therapy for ovarian cancer: current status and new treatments. Semin Oncol. 2006;33(2 suppl 6):S3-S11.
3. Perona R. Cell signalling: growth factors and tyrosine kinase receptors. Clin Transl Oncol. 2006;8:77-82.
4. Manley PW, Bold G, Bruggen J, et al. Advances in the structural biology, design and clinical development of VEGF-R kinase inhibitors for the treatment of angiogenesis. Biochim Biophys Acta. 2004;1697(1-2):17-27.
5. Klein S, McCormick F, Levitzki A. Killing time for cancer cells. Nat Rev Cancer. 2005;5:573-580.
6. George D. Platelet-derived growth factor receptors: a therapeutic target in solid tumors. Semin Oncol. 2001;28(5 suppl 17):27-33.
7. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344:1031-1037.
8. Buchdunger E, O'Reilly T, Wood J. Pharmacology of imatinib (STI571). Eur J Cancer. 2002;38(suppl 5):S28-S36.
9. Henriksen R, Funa K, Wilander E, Backstrom T, Ridderheim M, Oberg K. Expression and prognostic significance of platelet-derived growth factor and its receptors in epithelial ovarian neoplasms. Cancer Res. 1993;53:4550-4554.
10. Berman J, O'Leary TJ. Gastrointestinal stromal tumor workshop. Hum Pathol. 2001;32:578-582.
11. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347:472-480.
12. Jones AV, Cross NC. Oncogenic derivatives of platelet-derived growth factor receptors. Cell Mol Life Sci. 2004;61: 2912-2923.
13. Wilczynski SP, Chen YY, Chen W, Howell SB, Shively JE, Alberts DS. Expression and mutational analysis of tyrosine kinase receptors c-kit, PDGFRalpha, and PDGFRbeta in ovarian cancers. Hum Pathol. 2005;36:242-249.
14. Apte SM, Fan D, Killion JJ, Fidler IJ. Targeting the platelet-derived growth factor receptor in antivascular therapy for human ovarian carcinoma. Clin Cancer Res. 2004;10:897-908.
15. Schmandt RE, Broaddus R, Lu KH, et al. Expression of c-ABL, c-KIT, and platelet-derived growth factor receptor-beta in ovarian serous carcinoma and normal ovarian surface epithelium. Cancer. 2003;98:758-764.
16. Versnel MA, Haarbrink M, Langerak AW, et al. Human ovarian tumors of epithelial origin express PDGF in vitro and in vivo. Cancer Genet Cytogenet. 1994;73:60-64.
17. Ito M, Harada T, Tanikawa M, Fujii A, Shiota G, Terakawa N. Hepatocyte growth factor and stem cell factor involvement in paracrine interplays of theca and granulosa cells in the human ovary. Fertil Steril. 2001;75:973-979.
18. Lammie A, Drobnjak M, Gerald W, Saad A, Cote R, Cordon-Cardo C. Expression of c-kit and kit ligand proteins in normal human tissues. J Histochem Cytochem. 1994;42:1417-1425.
19. Parrott JA, Kim G, Skinner MK. Expression and action of kit ligand/stem cell factor in normal human and bovine ovarian surface epithelium and ovarian cancer. Biol Reprod. 2000;62:1600-1609.
20. Dushkin H, Schilder RJ. Imatinib mesylate and its potential implications for gynecologic cancers. Curr Treat Options Oncol. 2005;6:115-120.
21. Tchabo NE, Liel MS, Kohn EC. Applying proteomics in clinical trials: assessing the potential and practical limitations in ovarian cancer. Am J Pharmacogenomics. 2005;5: 141-148.
22. Therasse P, Eisenhauer EA, Verweij J. RECIST revisited: a review of validation studies on tumour assessment. Eur J Cancer. 2006;42:1031-1039.
23. Coleman RL, Broaddus RR, Bodurka DC, et al. Phase II trial of imatinib mesylate in patients with recurrent platinum-and taxane-resistant epithelial ovarian and primary peritoneal cancers. Gynecol Oncol. 2006;101:126-131.
24. Emmert-Buck MR, Bonner RF, Smith PD, et al. Laser capture microdissection. Science. 1996;274:998-1001.
25. Sheehan KM, Calvert VS, Kay EW, et al. Use of reverse phase protein microarrays and reference standard development for molecular network analysis of metastatic ovarian carcinoma. Mol Cell Proteomics. 2005;4:346-355.
26. Hollander M, Wolfe DA. Nonparametric Statistical Methods. 2nd ed. New York, NY: John Wiley and Sons, Inc.; 1999.
27. Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrica. 1988;75:800-802.
28. Litz J, Krystal GW. Imatinib inhibits c-Kit-induced hypoxia-inducible factor-1 alpha activity and vascular endothelial growth factor expression in small cell lung cancer cells. Mol Cancer Ther. 2006;5:1415-1422.
29. Liu P, Li J, Han ZC, et al. Elevated plasma levels of vascular endothelial growth factor is associated with marked splenomegaly in chronic myeloid leukemia. Leuk Lymphoma. 2005;46:1761-1764.
30. Legros L, Bourcier C, Jacquel A, et al. Imatinib mesylate (STI571) decreases the vascular endothelial growth factor plasma concentration in patients with chronic myeloid leukemia. Blood. 2004;104:495-501.
31. Ebos JM, Tran J, Master Z, et al. Imatinib mesylate (STI-571) reduces Bcr-Abl-mediated vascular endothelial growth factor secretion in chronic myelogenous leukemia. Mol Cancer Res. 2002;1:89-95.
32. Kim DJ, Lee MH, Park TI, Bae HI. Expression and mutational analysis of c-kit in ovarian surface epithelial tumors. J Korean Med Sci. 2006;21:81-85.
33. Khalifeh I, Munkarah AR, Schimp V, Morris R, Lawrence WD, Ali-Fehmi R. The impact of c-kit and ki-67 expression on patients' prognosis in advanced ovarian serous carcinoma. Int J Gynecol Pathol. 2005;24:228-234.
34. Matei D, Chang DD, Jeng M-H. Imatinib mesylate (Gleevec) inhibits ovarian cancer cell growth through a mechanism dependent on platelet-derived growth factor receptor alpha and Akt inactivation. Clin Cancer Res. 2004; 10:681-690.
35. Goldsby R, Pulsipher M, Adams R, Coffin C, Albritton K, Wagner L. Unexpected pleural effusions in 3 pediatric patients treated with STI-571. J Pediatr Hematol Oncol. 2002;24:694-695.
36. Moore JC, Dennehey CF, Anavim A, Kong KM, Tiong Ong S. Multiple joint effusions associated with high-dose imatinib therapy in a patient with chronic myelogenous leukaemia. Eur J Haematol. 2006;76:444-446.
37. Barton JC, Jones SC, Lamberth WC, Reymann MT, Scott VC. Cardiac tamponade associated with imatinib mesylate therapy of chronic myelogenous leukemia. Am J Hematol. 2002;71:139-140.
38. Breccia M, D'Elia GM, D'Andrea M, Latagliata R, Alimena G. Pleural-pericardic effusion as uncommon complication in CML patients treated with imatinib. Eur J Haematol. 2005;74:89-90.
39. Asschert JG, Vellenga E, Ruiters MH, de Vries EG. Regulation of spontaneous and TNF/IFN-induced IL-6 expression in two human ovarian-carcinoma cell lines. Int J Cancer. 1999;82:244-249.
40. Hefler LA, Grimm C, Ackermann S, et al. An interleukin-6 gene promoter polymorphism influences the biological phenotype of ovarian cancer. Cancer Res. 2003;63:3066-3068.
41. Hu YL, Tee MK, Goetzl EJ, et al. Lysophosphatidic acid induction of vascular endothelial growth factor expression in human ovarian cancer cells. J Natl Cancer Inst. 2001;93: 762-768.
42. Lu KH, Patterson AP, Wang L, et al. Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clin Cancer Res. 2004;10:3291-3300.
43. Zebrowski BK, Liu W, Ramirez K, Akagi Y, Mills GB, Ellis LM. Markedly elevated levels of vascular endothelial growth factor in malignant ascites. Ann Surg Oncol. 1999; 6:373-378.
44. Ostman A. PDGF receptors-mediators of autocrine tumor growth and regulators of tumor vasculature and stroma. Cytokine Growth Factor Rev. 2004;15:275-286.
45. Liotta LA, Kohn EC. The microenvironment of the tumour-host interface. Nature. 2001;411:375-379.
46. Kassis J, Klominek J, Kohn EC. Tumor microenvironment: what can effusions teach us? Diagn Cytopathol. 2005;33: 316-319.
47. Bono P, Krause A, von Mehren M, et al. Serum KIT and KIT ligand levels in patients with gastrointestinal stromal tumors treated with imatinib. Blood. 2004;103:2929-2935.
48. Mehta AI, Ross S, Lowenthal MS, et al. Biomarker amplification by serum carrier protein binding. Dis Markers. 2003;19:1-10.
49. Posadas EM, Liel MS, Kwitkowski V, et al. A phase lI and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer. Cancer. 2007;109:1323-1330.